Who are Bone Marrow Concentrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Concentrated Bone Marrow Aspirate Injection, ASC, Regenexx SD® procedure.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bone-marrow-concentrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Bone Marrow Concentrate — Competitive Intelligence Brief

Bone Marrow Concentrate (Bone Marrow Concentrate) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous stem cell therapy. Area: Orthopedics / Regenerative Medicine.

phase 3 Autologous stem cell therapy Orthopedics / Regenerative Medicine Biologic Live · refreshed every 30 min

Target snapshot

Bone Marrow Concentrate (Bone Marrow Concentrate) — Istituto Ortopedico Rizzoli. Bone marrow concentrate delivers a heterogeneous population of stem cells and growth factors to promote tissue regeneration and repair.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Bone Marrow Concentrate TARGET	Bone Marrow Concentrate	Istituto Ortopedico Rizzoli	phase 3	Autologous stem cell therapy
Concentrated Bone Marrow Aspirate Injection	Concentrated Bone Marrow Aspirate Injection	Hospital for Special Surgery, New York	marketed	Autologous stem cell therapy
ASC	ASC	Anterogen Co., Ltd.	marketed	Autologous stem cell therapy
Regenexx SD® procedure	Regenexx SD® procedure	Regenexx, LLC	phase 3	Autologous stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous stem cell therapy class)

Anterogen Co., Ltd. · 1 drug in this class
Hospital for Special Surgery, New York · 1 drug in this class
Istituto Ortopedico Rizzoli · 1 drug in this class
Regenexx, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bone Marrow Concentrate — Competitive Intelligence Brief. https://druglandscape.com/ci/bone-marrow-concentrate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab